IGF-1 LR3, or Long R3 IGF-1, is a modified analog of IGF-1 engineered for laboratory use and widely sold online as a research chemical. It has no approved human use and no meaningful human clinical trial evidence. Understanding what was modified explains why.
This guide situates IGF-1 LR3 within the broader field of peptide therapy and is written for clinicians. It is clinical education, not medical advice, and nothing here should be read as a treatment recommendation or protocol.
What is IGF-1 LR3?
IGF-1 LR3 carries two deliberate modifications to the native IGF-1 sequence: an arginine substituted at position 3, and a 13-amino-acid extension added to the N-terminus. The name encodes both — "Long" for the extension, "R3" for the arginine.
It was developed as a cell culture reagent, not as a therapeutic. Its purpose was to supply potent, sustained IGF-1 receptor stimulation in laboratory systems where binding proteins secreted by cultured cells would otherwise blunt the signal.
Why the modifications matter
In the body, IGF-1 circulates almost entirely bound to IGF binding proteins, with only a small free fraction active at any time. That binding system is not an inefficiency — it is a regulatory buffer that controls how much signal reaches tissue and when.
The arginine substitution dramatically reduces binding protein affinity. The result is a molecule that circulates largely unbound, with far more free activity and a half-life extended from minutes to many hours.
This is the entire safety problem in one sentence: the modification removes the body's principal mechanism for regulating IGF-1 activity. A reagent designed to defeat physiologic control is a poor candidate for administration to a physiologic system.
The risk profile
Two risks follow directly. First, hypoglycemia: IGF-1 has meaningful insulin receptor activity, and an analog with sustained high free concentrations amplifies that effect well beyond what native IGF-1 produces. Approved mecasermin already requires dosing with food specifically to manage this — and mecasermin is the regulated version.
Second, mitogenic signaling. IGF-1 promotes cell proliferation and inhibits apoptosis. Approved recombinant IGF-1 is contraindicated in active or suspected malignancy for this reason. An analog engineered for sustained supraphysiologic receptor activation raises that theoretical concern rather than reducing it, and no human safety data exist to characterize it.
There is no adequate human clinical evidence for efficacy or safety at any dose or duration. Material sold online is unregulated, with no verified identity, purity, or concentration — a serious matter for a compound whose principal acute risk is hypoglycemia.
What to tell patients
IGF-1 LR3 appears in bodybuilding protocols and is often described as a more effective form of IGF-1. That description is accurate about potency and silent about why the potency exists.
The clear clinical statement is that this is a laboratory reagent engineered to bypass the body's own regulation of a growth-promoting, insulin-active hormone, sold outside the regulated supply, with no human safety data. A patient using it should at minimum be assessed for hypoglycemia risk. For what the GH/IGF-1 axis can realistically deliver, our growth hormone peptides guide covers the class honestly.
Learn peptides the right way
Empire Medical Training's Peptide Therapy Master Course is a CME-accredited program covering the GH/IGF-1 axis and its interpretation, patient selection, monitoring, regulatory status, and compliant sourcing — taught by board-certified physicians. Available in person and via livestream. It is also Course 1 of Empire’s Peptide Therapy Certification, which adds business, marketing and healthcare-law training, a documented case series and a final exam.
Explore the Certification →